Comparing Platinum-based Therapy with TSR-042 and Niraparib to Standard Treatment for Advanced Ovarian Cancer

Inclusion Criteria

• Women aged 18 or older who understand and agree to participate in the study.
• Diagnosed with high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer at stage III or IV.
• Eligible if they have stage IV disease or meet specific criteria for stage III.
• Must provide blood and tumor samples for specific genetic testing.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control during the study and for 180 days after the last treatment.
• Must have good organ function and be in generally good health with controlled blood pressure.
• Must agree to complete quality of life questionnaires and be able to take oral medication.

Exclusion Criteria

• Have a different type of ovarian cancer, such as mucinous or low-grade tumors.
• Have not fully recovered from major surgery.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have active brain cancer or significant heart disease.
• Have bowel obstructions or certain serious abdominal conditions.
• Have a history of certain blood disorders or have had another invasive cancer within the last 5 years.
• Have a high risk of bleeding or are immunocompromised.
• Have active hepatitis B or C infections.
• Have received other investigational treatments recently or have allergies to study drugs.
• Have an active autoimmune disease requiring treatment in the past 2 years.